These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 39067873)

  • 1. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort.
    Patel SP; Othus M; Chae YK; Huynh T; Tan B; Kuzel T; McLeod C; Lopez G; Chen HX; Sharon E; Streicher H; Ryan CW; Blanke C; Kurzrock R
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39067873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.
    Chae YK; Othus M; Patel S; Powers B; Hsueh CT; Govindarajan R; Bucur S; Kim HS; Chung LI; McLeod C; Chen HX; Sharon E; Streicher H; Ryan CW; Blanke C; Kurzrock R
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39343510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
    Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
    Patel SP; Guadarrama E; Chae YK; Dennis MJ; Powers BC; Liao CY; Ferri WA; George TJ; Sharon E; Ryan CW; Othus M; Lopez G; Blanke CD; Kurzrock R
    Cancer; 2024 Sep; 130(17):2918-2927. PubMed ID: 38358334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
    Patel SP; Othus M; Chae YK; Giles FJ; Hansel DE; Singh PP; Fontaine A; Shah MH; Kasi A; Baghdadi TA; Matrana M; Gatalica Z; Korn WM; Hayward J; McLeod C; Chen HX; Sharon E; Mayerson E; Ryan CW; Plets M; Blanke CD; Kurzrock R
    Clin Cancer Res; 2020 May; 26(10):2290-2296. PubMed ID: 31969335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
    Patel SP; Mayerson E; Chae YK; Strosberg J; Wang J; Konda B; Hayward J; McLeod CM; Chen HX; Sharon E; Othus M; Ryan CW; Plets M; Blanke CD; Kurzrock R
    Cancer; 2021 Sep; 127(17):3194-3201. PubMed ID: 33882143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
    Adams S; Othus M; Patel SP; Miller KD; Chugh R; Schuetze SM; Chamberlin MD; Haley BJ; Storniolo AMV; Reddy MP; Anderson SA; Zimmerman CT; O'Dea AP; Mirshahidi HR; Ahnert JR; Brescia FJ; Hahn O; Raymond JM; Biggs DD; Connolly RM; Sharon E; Korde LA; Gray RJ; Mayerson E; Plets M; Blanke CD; Chae YK; Kurzrock R
    Clin Cancer Res; 2022 Jan; 28(2):271-278. PubMed ID: 34716198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
    Patel SP; Othus M; Chae YK; Dennis MJ; Gordon S; Mutch D; Samlowski W; Robinson WRR; Sharon E; Ryan C; Lopez G; Plets M; Blanke C; Kurzrock R
    Clin Cancer Res; 2024 Jan; 30(1):33-38. PubMed ID: 37882676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
    Klein O; Kee D; Markman B; Michael M; Underhill C; Carlino MS; Jackett L; Lum C; Scott C; Nagrial A; Behren A; So JY; Palmer J; Cebon J
    Clin Cancer Res; 2020 Sep; 26(17):4454-4459. PubMed ID: 32532787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
    BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.
    Klein O; Senko C; Carlino MS; Markman B; Jackett L; Gao B; Lum C; Kee D; Behren A; Palmer J; Cebon J
    Oncoimmunology; 2021 Apr; 10(1):1908771. PubMed ID: 33889439
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
    Schoenfeld JD; Hanna GJ; Jo VY; Rawal B; Chen YH; Catalano PS; Lako A; Ciantra Z; Weirather JL; Criscitiello S; Luoma A; Chau N; Lorch J; Kass JI; Annino D; Goguen L; Desai A; Ross B; Shah HJ; Jacene HA; Margalit DN; Tishler RB; Wucherpfennig KW; Rodig SJ; Uppaluri R; Haddad RI
    JAMA Oncol; 2020 Oct; 6(10):1563-1570. PubMed ID: 32852531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
    Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
    Zamarin D; Burger RA; Sill MW; Powell DJ; Lankes HA; Feldman MD; Zivanovic O; Gunderson C; Ko E; Mathews C; Sharma S; Hagemann AR; Khleif S; Aghajanian C
    J Clin Oncol; 2020 Jun; 38(16):1814-1823. PubMed ID: 32275468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
    Oaknin A; Moore K; Meyer T; López-Picazo González J; Devriese LA; Amin A; Lao CD; Boni V; Sharfman WH; Park JC; Tahara M; Topalian SL; Magallanes M; Molina Alavez A; Khan TA; Copigneaux C; Lee M; Garnett-Benson C; Wang X; Naumann RW
    Lancet Oncol; 2024 May; 25(5):588-602. PubMed ID: 38608691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
    Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
    Klein O; Kee D; Nagrial A; Markman B; Underhill C; Michael M; Jackett L; Lum C; Behren A; Palmer J; Tebbutt NC; Carlino MS; Cebon J
    JAMA Oncol; 2020 Sep; 6(9):1405-1409. PubMed ID: 32729929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
    Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
    Cohen R; Bennouna J; Meurisse A; Tournigand C; De La Fouchardière C; Tougeron D; Borg C; Mazard T; Chibaudel B; Garcia-Larnicol ML; Svrcek M; Vernerey D; Menu Y; André T
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33148693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer.
    Chae YK; Othus M; Patel SP; Wilkinson KJ; Whitman-Purves EM; Lea J; Schallenkamp JM; Adra N; Appleman LJ; Alden M; Thomes Pepin J; Ellerton JA; Poklepovic A; Walter A; Rampurwala MM; Robinson WR; Kim HS; Chung LI; McLeod CM; Lopez G; Chen HX; Sharon E; Streicher H; Ryan CW; Blanke CD; Kurzrock R
    Clin Cancer Res; 2024 Oct; ():. PubMed ID: 39417692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.